Collegium Announces the Addition of Xtampza ER to Express Scripts’ Formulary

15 December, 2016

CANTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has finalized its contract with Express Scripts, the largest pharmacy benefits management (PBM) in the United States.  Pursuant to the contract, Xtampza ER is covered on the 2017 Express Scripts’ National Preferred Formulary.

“The addition of another 28 million contracted lives in the commercial channel is an important step towards broader reimbursement for Xtampza,” stated Michael Heffernan, Collegium’s CEO. “Since the commercial launch of Xtampza last summer, we’ve made significant progress securing payer commitments, ensuring pharmacy availability, and increasing the physician prescriber base of Xtampza ER.”